The Best Guess Approach To Phase I Trial Design
作者： Daniela D. Rosa , John Harris , Gordon C. Jayson
关键词:
摘要: Rosa, Daniela D Harris, John Jayson, Gordon C Case Reports United States Journal of clinical oncology : official journal the American Society Clinical Oncology J Clin Oncol. 2006 Jan 1;24(1):206-8.
manchester.ac.uk
openrepository.com参考文章(36)
S.M. Gadgeel, R.R. Boinpally, L.K. Heilbrun, A. Wozniak, V. Jain, B. Redman, M. Zalupski, R. Wiegand, R. Parchment, P.M. LoRusso, A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Investigational New Drugs. ,vol. 21, pp. 63- 74 ,(2003) , 10.1023/A:1022972427532
Edward L. Korn, Susan G. Arbuck, James M. Pluda, Richard Simon, Richard S. Kaplan, Michaele C. Christian, Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed? Journal of Clinical Oncology. ,vol. 19, pp. 265- 272 ,(2001) , 10.1200/JCO.2001.19.1.265
B. C. Goh, M. J. Ratain, D. Bertucci, R. Smith, S. Mani, N. J. Vogelzang, R. L. Schilsky, M. Hutchison, M. Smith, S. Averbuch, E. Douglass, Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations Journal of Clinical Oncology. ,vol. 19, pp. 1476- 1484 ,(2001) , 10.1200/JCO.2001.19.5.1476
John O'Quigley, Sylvie Chevret, Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Statistics in Medicine. ,vol. 10, pp. 1647- 1664 ,(1991) , 10.1002/SIM.4780101104
James A. Bolognese, A Monte Carlo comparison of three up-and-down designs for dose ranging Controlled Clinical Trials. ,vol. 4, pp. 187- 196 ,(1983) , 10.1016/S0197-2456(83)80024-5
Helen L. Anderson, Jeffrey T. Yap, Mathew P. Miller, Adele Robbins, Terry Jones, Patricia M. Price, Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate Journal of Clinical Oncology. ,vol. 21, pp. 2823- 2830 ,(2003) , 10.1200/JCO.2003.05.186
D.R. Newell, J. Silvester, C. McDowell, S.S. Burtles, The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. European Journal of Cancer. ,vol. 40, pp. 899- 906 ,(2004) , 10.1016/J.EJCA.2003.12.020
Ch Dittrich, G Greim, M Borner, K Weigang-Köhler, H Huisman, A Amelsberg, A Ehret, J Wanders, A Hanauske, P Fumoleau, EORTC Early Clinical Studies Group (ECSG, Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. European Journal of Cancer. ,vol. 38, pp. 1072- 1080 ,(2002) , 10.1016/S0959-8049(02)00020-5
Razelle Kurzrock, Robert S. Benjamin, Risks and Benefits of Phase 1 Oncology Trials, Revisited The New England Journal of Medicine. ,vol. 352, pp. 930- 932 ,(2005) , 10.1056/NEJME058007